Strydaflex Injectable

Polysulfated glycosaminoglycan (PSGAG) injectable for equine joint disease and soft tissue injuries; supports articular cartilage. Polysulfated glycosaminoglycan (PSGAG) injectable (equine brand). Mechanism: inhibits destructive cartilage enzymes (MMPs, stromelysin, elastase, hyaluronidase, complement); stimulates chondrocyte proteoglycan and HA synthesis; exhibits anti-inflammatory and heparin-like properties. IM administration for joint disease in horses. Key information Equine joint supplement injectable or oral. Store per label. For joint health support. Aseptic technique if injectable.

IM injection: administer deep IM. Standard equine protocol: 500 mg IM twice weekly for 4 weeks. Intra-articular: strict aseptic technique. Store at room temperature; protect from light. If a dose is missed This product is given as a single dose or as part of a defined protocol. Contact your veterinarian if a scheduled administration was missed. Contact your veterinarian.

IM injection site reactions (pain, swelling). Mild transient thrombocytopenia (heparin-like). Hypersensitivity (rare). Anticoagulant effect — exercise caution with concurrent anticoagulants.

For animals Mild anticoagulant effect — use with caution in horses with coagulopathy or concurrent anticoagulant therapy. Not approved for use in food-producing animals. For people handling this medication Wear gloves when handling. Wash hands thoroughly with soap and water after handling. PSGAG injectable — wear gloves. Heparin-like: avoid skin contact with injectable. Avoid contact with eyes; if contact occurs, flush with water for 15 minutes and seek medical attention.

Contact your veterinarian. Joint supplement overdose — contact vet for guidance.